Literature DB >> 10195721

Sentinel lymph node biopsy in breast cancer: unfiltered radioisotope is superior to filtered.

D C Linehan1, A D Hill, K N Tran, H Yeung, S D Yeh, P I Borgen, H S Cody.   

Abstract

BACKGROUND: The combination of gamma-probe radiolocalization and blue-dye mapping of sentinel lymph nodes (SLNs) has been advocated as the most accurate method for staging the clinically negative axilla in breast cancer patients, but the technical aspects of these procedures are not fully characterized in the literature. In this study, we compared the success of SLN localization in 134 consecutive breast cancer patients using blue dye plus two different preparations of radiocolloid. STUDY
DESIGN: A retrospective analysis of a prospectively maintained data base was performed to assess SLN localization in two cohorts of patients. Unfiltered technetium-99m (Tc-99m) sulfur colloid (in 77 patients; group I) was compared with filtered Tc-99m sulfur colloid (in 57 patients; group II). All patients had a peritumoral injection of blue dye and isotope, followed immediately by lymphoscintigraphy to confirm radioactivity at the injection site and to image the SLN. Statistical analysis was performed using the Pearson chi-square test.
RESULTS: Unfiltered Tc-99m sulfur colloid was superior to the filtered radiocolloid in localizing the SLN (88% versus 73%; p = 0.03). SLN imaging by lymphoscintigraphy was also more successful in the unfiltered group. Using the combination of blue dye and radiolocalization, SLNs were identified in 94% of patients.
CONCLUSIONS: For optimal localization of the SLN in breast cancer patients, surgeons should use the combined technique of blue-dye mapping and gamma-probe localization using unfiltered Tc-99m sulfur colloid.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195721     DOI: 10.1016/s1072-7515(98)00314-7

Source DB:  PubMed          Journal:  J Am Coll Surg        ISSN: 1072-7515            Impact factor:   6.113


  7 in total

Review 1.  Sentinel node detection in pre-operative axillary staging.

Authors:  Giuseppe Trifirò; Giuseppe Viale; Oreste Gentilini; Laura Lavinia Travaini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

Review 2.  The efficacy of Tilmanocept in sentinel lymph mode mapping and identification in breast cancer patients: a comparative review and meta-analysis of the ⁹⁹mTc-labeled nanocolloid human serum albumin standard of care.

Authors:  Christopher A Tokin; Frederick O Cope; Wendy L Metz; Michael S Blue; Beth M Potter; Bonnie C Abbruzzese; Richard D Hartman; Marcus T Joy; Dennis W King; Lori A Christman; David R Vera; Anne M Wallace
Journal:  Clin Exp Metastasis       Date:  2012-06-23       Impact factor: 5.150

3.  Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes.

Authors:  K M McMasters; S L Wong; T M Tuttle; D J Carlson; C M Brown; R Dirk Noyes; R L Glaser; D J Vennekotter; P S Turk; P S Tate; A Sardi; M J Edwards
Journal:  Ann Surg       Date:  2000-05       Impact factor: 12.969

4.  Sentinel lymphnode biopsy in early breast cancer using methylene blue dye and radioactive sulphur colloid - a single institution Indian experience.

Authors:  S P Somashekhar; S Zaveri Shabber; K Udupa Venkatesh; K Venkatachala; M M Vasan Thirumalai
Journal:  Indian J Surg       Date:  2008-07-24       Impact factor: 0.656

Review 5.  Clinical aspects of sentinel node biopsy.

Authors:  H S Cody
Journal:  Breast Cancer Res       Date:  2001-01-23       Impact factor: 6.466

6.  A novel method for sentinel lymph node biopsy by indocyanine green fluorescence technique in breast cancer.

Authors:  Tomoharu Sugie; Kassim Abdelazeem Kassim; Megumi Takeuchi; Takashi Hashimoto; Kazuhiko Yamagami; Yoshikazu Masai; Masakazu Toi
Journal:  Cancers (Basel)       Date:  2010-04-27       Impact factor: 6.639

7.  Comparison of the indocyanine green dye method versus the combined method of indigo carmine blue dye with indocyanine green fluorescence imaging for sentinel lymph node biopsy in breast conservative therapy for stage ≤IIA breast cancer.

Authors:  Nobuyuki Takemoto; Ai Koyanagi; Masanori Yasuda; Hiroshi Yamamoto
Journal:  BMC Womens Health       Date:  2018-09-18       Impact factor: 2.809

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.